BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302252% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines BRUKINSA — China Net Product Revenue by Year
BRUKINSA — China Net Product Revenue ($M) ($M)
BeOne Medicines BRUKINSA — China Net Product Revenue: $344M in FY2025, up 33.3% from a year earlier.
Latest, FY2025
344
Period ended Dec 31, 2025
Change on a year earlier
+33.3%
258 in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Where the FY2025 figure comes from
“BRUKINSA sales in China totaled $344.1 million for the year ended December 31, 2025, representing growth of 33.3%”
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BRUKINSA — China Net Product Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 344 | +33.3% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 258 | +33.2% | Form 10-K (filed 2025-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 194 | +28.9% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 150 | +48.5% | Form 10-K (filed 2023-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 101 | – | Form 10-K (filed 2022-02-28) ↗ |
Breakdown
What makes up BRUKINSA — China Net Product Revenue
Cite this data
StockData. (2026). BeOne Medicines BRUKINSA — China Net Product Revenue ($M), annual FY2021–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-brukinsa-cn
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.